Real-world evidence: a primer
They also point out that the full uACR improvement seemed to occur before the maximal effect on body weight was achieved. They made what, to me, is an odd claim that four weeks after discontinuation of semaglutide, body weight only modestly increased. In fact, even though this drug has a long half life, between weeks 24 and 28 the median weight returned to the same level seen at around 21 weeks, meaning the average weight regain was three weeks of weight loss over four weeks, with the drug at least somewhat still in their systems
[11] [53] [54] [55] Primary pulmonary hypertension (PPH) and cardiac valvulopathy (regurgitant cardiac valvular disease) have been reported with phentermine
The weight-loss benefits of these drugs have led to their prescribed use for obesity or overweight treatment
Not FDA-approved and not intended to diagnose, treat, cure, or prevent any disease
Both oral and injectable tirzepatide carry the same safety profile and side-effect risk because they contain identical active compounds
